The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

Martin E. Dowty; Jinyan Lin; Tim F. Ryder; Weiwei Wang; Gregory S. Walker; Alfin Vaz; Gary L. Chan; Sriram Krishnaswami; Chandra Prakash

doi:10.1124/dmd.113.054940

Research ArticleArticle

The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

Martin E. Dowty, Jinyan Lin, Tim F. Ryder, Weiwei Wang, Gregory S. Walker, Alfin Vaz, Gary L. Chan, Sriram Krishnaswami and Chandra Prakash

Drug Metabolism and Disposition April 2014, 42 (4) 759-773; DOI: https://doi.org/10.1124/dmd.113.054940

Martin E. Dowty

Department of Pharmacokinetics, Dynamics, and Metabolism, Pfizer Inc., Andover, Massachusetts (M.E.D.); Pfizer Inc., Groton, Connecticut (J.L., T.F.R., W.W., G.S.W., A.V., C.P.); and Departments of Specialty Care Clinical Affairs (G.L.C.) and Clinical Pharmacology (S.K.), Pfizer Inc., Groton, Connecticut

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jinyan Lin

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tim F. Ryder

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Weiwei Wang

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gregory S. Walker

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alfin Vaz

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Gary L. Chan

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sriram Krishnaswami

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chandra Prakash

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

Submit a Response to This Article

Compose eLetter

Title *

Contents

More information about text formats

Plain text

No HTML tags allowed.
Web page addresses and e-mail addresses turn into links automatically.
Lines and paragraphs break automatically.

Author Information

Contributors
First Name and Middle Initial * First or given name, e.g. 'Peter'. Last Name * Your last, or family, name, e.g. 'MacMoody'. Email Address * Your email address, e.g. higgs-boson@gmail.com Occupation * Your role and/or occupation, e.g. 'Orthopedic Surgeon'. Affiliation * Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.

Statement of Competing Interests

Competing interests? *

Yes

Please describe the competing interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.

PreviousNext

In this issue

Drug Metabolism and Disposition

Vol. 42, Issue 4

1 Apr 2014

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans

Message Subject (Your Name) has forwarded a page to you from Drug Metabolism & Disposition

Message Body (Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleArticle